Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.

ABSTRACT:

Background

The prognosis of patients with advanced biliary tract cancer (BTC) is extremely poor and only a few standard treatments are available for this condition. We performed a phase I trial to investigate the safety, immune response and anti-tumor effect of vaccination with three peptides derived from cancer-testis antigens.

Methods

This study was conducted as a phase I trial. Nine patients with advanced BTC who had unresectable tumors and were refractory to standard chemotherapy were enrolled. Three HLA-A*2402 restricted epitope peptides-cell division cycle associated 1 (CDCA1), cadherin 3 (CDH3) and kinesin family member 20A (KIF20A)-were administered subcutaneously, and the adverse events and immune response were assessed. The clinical effects observed were the tumor

SUBMITTER: Aruga A 

PROVIDER: S-EPMC4015445 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature